COMPASS Pathways granted two US patents London, UK 23 March 2021 COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in … LONDON, Jan. 13, 2020 /PRNewswire/ -- COMPASS Pathways, a mental health care company, announced today that it has been granted US Patent No 10,519,175, relating to methods of treating drug-resistant Last week, COMPASS Pathways announced its acquisition of US Patent No 10,591,175. Psilocybin! Compass Pathways Ltd Original Assignee Compass Pathways Ltd Priority date (The priority date is an assumption and is not a legal conclusion. The … The path to legalization for cannabis has been a long and bumpy road, and it is far from over. ... which were rejected by both the US and EU patent offices. 2017-10-09 Filing date 2017-10-09 Publication date 2017-11-22 Family has litigation COMPASS Pathways Acquires Patent for Psilocybin, Which May Help with Depression. More specifically, COMPASS has locked down “methods of treating drug-resistant depression with a psilocybin formulation.” The company is also running a phase IIb clinical trial of its patented formulation, COMP360, which we covered in a blog post It is unrealistic for the COMPASS Pathways to file a patent for a psychotherapy session as it is a procedure, not a drug. However, COMPASS succeeded in the US with one patent … Post-grant review is a trial proceeding at the PTAB that permits a third party to challenge the validity of claims of a granted patent. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) The UK-based mental health care company Compass Pathways Ltd announced in January that it had been granted a US patent for a formulation of crystalline psilocybin in a therapy protocol for patients with treatment-resistant depression. Compass Pathways COMP360 psilocybin patent Psymposia. LONDON, Jan. 13, 2020 /PRNewswire/ -- COMPASS Pathways, a mental health care company, announced today that it has been granted US Patent No … The conversation began last month when Compass Pathways (NASDAQ:CMPS) introduced a series of patent applications for elements of psilocybin-assisted therapy as … These patents cover oral formulations of COMPASS’s synthetic psilocybin in the treatment … Compass Pathways Limited, Pet. for Post-Grant Review, PGR2020-00030, filed February 21, 2020) (“Compass Pathways”). London, UK – 23 March 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted two new patents by the US Patent and Trademark Office (USPTO). Now, advocates of magic mushrooms are seemingly getting geared up after the acquisition of a patent for a trial involving psilocybin and depression. A major flashpoint in the debate took place in February, when Compass Pathways filed a patent application for psychedelic therapy using the shrooms compound psilocybin. What does that patent cover?